“Epigenetics market was valued at USD 7.10 billion in 2018 and is expected to reach USD 19.12 billion by the year 2026, at a CAGR of 13.1%”
Maybe we see a billion to 3 in the next couple years? Still believe we won’t see a deal until Q-4 at which time many of the trials are wrapping up so probably more like Q1-Q2 2025.
Not sure how rvx survives , probably more extensions from Hepalink & Eversana and a lot more cheap shares flying out the door to cover wages & donnys hard work/excitment with absolutely nothing new to report in 2024..... maybe another paper or two regarding mice.
If we ever had a lead I believe this ceo & bod have completely blown it through sheer incompetence.
